Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.58), $0.10 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $475 thousand versus the consensus estimate of $470 thousand.

“This is an important time for Ocular Therapeutix as we approach the PDUFA target action date for our lead product candidate, DEXTENZA, for the treatment of ocular pain following ophthalmic surgery,” said Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman. “Should DEXTENZA be approved, its commercial launch will enable our transition into a fully-integrated, commercial-stage, revenue-generating company. DEXTENZA has now been extensively studied for the treatment of post-surgical ocular pain and inflammation in over 550 clinical trial participants. If approved, we believe DEXTENZA will address the compliance issues associated with steroid eyedrops and serve as an attractive alternative for both patients and ophthalmologists.”

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.